Whi7 is an unstable cell-cycle repressor of the Start transcriptional program

Mercè Gomar-Alba¹, Ester Méndez¹, Inma Quilis¹, M. Carmen Bañó¹ & J. Carlos Igual¹

Start is the main decision point in eukaryotic cell cycle in which cells commit to a new round of cell division. It involves the irreversible activation of a transcriptional program by G1 CDK-cyclin complexes through the inactivation of Start transcriptional repressors, Whi5 in yeast or Rb in mammals. Here we provide novel keys of how Whi7, a protein related at sequence level to Whi5, represses Start. Whi7 is an unstable protein, degraded by the SCF^Grr1 ubiquitin-ligase, whose stability is cell cycle regulated by CDK1 phosphorylation. Importantly, Whi7 associates to G1/S gene promoters in late G1 acting as a repressor of SBF-dependent transcription. Our results demonstrate that Whi7 is a genuine paralog of Whi5. In fact, both proteins collaborate in Start repression bringing to light that yeast cells, as occurs in mammalian cells, rely on the combined action of multiple transcriptional repressors to block Start transition.
Cell cycle progression is controlled by a sophisticated regulatory system in which integrated networks of switch-like mechanisms help to organize an ordered succession of distinct cyclin-dependent kinase (CDK) activities that trigger the different cell cycle events. Two fundamental molecular processes are at the core of the cell cycle control system: gene expression and protein degradation. They govern the temporally and orderly accumulation of key cell cycle regulators and many other proteins required for cell cycle events.

The major point in cell cycle control occurs at the end of G1 phase in a process called Start in yeast and Restriction Point in mammalian cells. At this stage, cells decide to initiate or not a new round of cell division. Molecular strategy is extraordinarily well conserved between yeast and mammals. It involves the activation by specific CDK kinases of a transcriptional program involving hundred of genes, which provides the coherent expression of key cell cycle regulators and the cellular machineries required for the early events of the cell cycle. Failure to properly regulate cell cycle entry can result in abnormal division and lead to cancer.

In Saccharomyces cerevisiae, Start transcriptional gene expression depends on two related transcription factors: SBF and MBF. Both are heterodimeric complexes constituted by a common regulatory subunit, Swi6, and a different but related sequence-specific DNA binding protein, Swi4 in SBF and Mbp1 in MBF. SBF controls expression, among others, of CLN1 and CLN2 G1 cyclin genes and genes encoding proteins involved in morphogenesis. MBF regulates periodic expression of genes involved in DNA metabolism and CLB5 and CLB6 S-phase cyclin genes. Although each factor preferentially regulates specific genes, they show significant functional overlap. This redundancy and the importance of this transcription program are emphasized by the lethality of swi4swi6 and swi4mbp1 double mutants.

Transcriptional activation at G1/S is regulated by the G1 CDK-cyclin activities (Cdc28 associated with G1 cyclins Cln1, Cln2, and Cln3 in the case of S. cerevisiae). It follows a complex ordered series of events. SBF binds to target promoters in early G1, but due to the binding of Whi5 transcriptional repressor, it does not initiate transcription until late in G1. Activation of Start gene expression is initially promoted by the Cln3-Cdc28 kinase. In early G1, Cln3-Cdc28 is attached to the endoplasmic reticulum membrane (ER). Later on in G1, the chaperone Ydj1 releases Cln3-Cdc28 from the reticulum, allowing its nuclear accumulation. Then, Cln3-Cdc28 promotes the dissociation of Whi5, triggering transcription. As a result, kinases Cln1,2-Cdc28 accumulate and act on Whi5, SBF, and MBF to strengthen a genome-wide transcriptional response and to establish a positive feedback loop that drives cellular commitment and gives coherence to G1-S transition.

Different scenarios have been recently proposed on how activation of the transcriptional program could be integrated with cell growth. They included the dilution of Whi5 due to cell growth.

**Fig. 1** Cell cycle regulation of Whi7. cdc15 cells expressing GFP-tagged Whi7, HA-tagged Clb2, and myc-tagged Sic1 (JCY1802) were arrested in telophase by incubation at 37 °C. After 3 h, cells were transferred to 25 °C and cell cycle progression was analyzed at the indicated time. a Graph shows the distribution of cells at different cell cycle stages. b Whi7, Clb2, and Sic1 proteins, as well as Cdc28 as loading control, were analyzed by western blot; left graph shows the relative amount of each protein referred to the most abundant sample; right graph represents the percent of total Whi7 protein present as slow migrating bands. MCY123 and no tagged cdc15 strains were included in western analysis as controls.
the competition between cell growth and cell cycle entry for the Ydj1 chaperone and the titration of increasing amounts of Cln3 molecules due to cell growth against the constant number of SBF binding sites in DNA.

Later in the cell cycle, both SBF and MBF dependent transcription are silenced by different mechanisms. While SBF is inactivated by phosphorylation by Clb-Cdc28 kinases, transcriptional repressor Nrm1 acts via a negative feedback to inactivate MBF after G1/S transition. In addition to Whi5 and Nrm1, other proteins associate with SBF and MBF. Msa1 and Msa2 bind both factors, playing a role in response to stress or in the transition to quiescence. The Swi6-interacting protein Stb1 is
required for efficient repression previous to Start\textsuperscript{23, 28} and sharp periodic expression preferentially in MBF regulated genes\textsuperscript{29, 30}. Also, the Pcl9-Pho85 CDK associates to promoters and through Whi5 phosphorylation collaborates with Cln-Cdc28 in transcriptional activation\textsuperscript{31}.

The second major mechanism affecting the levels of cell cycle regulators is proteolysis mediated by ubiquitination and degradation in the proteasome. Two ubiquitin ligases are important in cell cycle regulation: SCF, critical for G1/S transition, and APC, essential in mitosis\textsuperscript{32–35}. SCF consists of four subunits: Skp1, Cdc53, Rbx1, and a F-box protein which is responsible for substrate recognition. Two F-proteins are involved in the degradation of most cell cycle regulators: Grr1 degrades degradation of G1 Cln cyclins whereas Cdc4 controls CKI Sic1 degradation. However, some overlapping sets of substrates may exist\textsuperscript{36}. Recognition of substrate by SCF requires the phosphorylation of specific residues\textsuperscript{35, 37}.

Whi7/Srl3 was originally identified as a multicopy suppressor of rad53 lethality\textsuperscript{38}. It constitutes together with Whi5 and Nrm1 a family protein characterized by the presence of the GTB (G1/S transcription factor binding) motif. In the case of Whi5 and Nrm1, this motif mediates transcriptional repression binding to SBF or MBF, respectively\textsuperscript{39}. Unlike whi5 mutant, whi7 does not present a small cell size phenotype in asynchronous cultures, apparently discarding a role in cell cycle initiation\textsuperscript{10, 40}. However, very recently Whi7 has been connected to Start regulation at its

![Fig. 3](https://example.com/fig3.png)

**Fig. 3** Cell cycle regulation of Whi7 protein stability by Cdc28 phosphorylation. 

\textbf{a} Cells of the WHI7-HA (JCY1728) strain were incubated for 2 h in the presence of 15 μg mL\textsuperscript{-1} nocodazole (>90% of cells arrested at G2/M phase). Whi7 protein stability was analyzed as described in Fig. 2. 

\textbf{b} Wild-type (JCY1746) and cdc15\textsuperscript{mutant} (JCY1802) cells expressing GFP-tagged Whi7 were incubated at 37 °C for 3 h (>95% of cdc15 mutant cells arrested at telophase), and then Whi7 protein stability was analyzed. 

\textbf{c} left panel: cdc15 cells expressing GFP-tagged Whi7 (JCY1802) were arrested in telophase by incubation at 37 °C. After 3 h, cells were released from the arrest and after 50 min, 100 μg mL\textsuperscript{-1} cycloheximide was added. Whi7, as well as Clb2 and Sic1 as controls of cell cycle progression, were analyzed. No budding occurred during the experiment confirming that cells remain in G1 phase. right panel: wild type (JCY1746) and GAL1:CLN3 cln1 cln2 (JCY2008) cells expressing GFP-tagged Whi7 were grown on galactose, transferred to YPD medium and after 3 h (100% of cell in G1 in the mutant strain) Whi7 protein stability was analyzed. 

\textbf{d} Wild type (JCY1746) and cdc28\textsuperscript{mutant} (JCY1789) cells expressing GFP-tagged Whi7 were incubated at 37 °C for 3 h and then Whi7 protein stability was analyzed. 

\textbf{e} Whi7 protein stability in whi7\textsuperscript{mutant} cells (JCY1819) transformed with a centromeric plasmid that expresses the HA-tagged wild type (pWHI7) or a mutated protein in all consensus CDK phosphorylation sites (pWhi7-NP)
earliest steps. Concretely, Whi7 helps to retain Cln3 in the ER membrane, a function that is inhibited by CDK dependent phosphorylation.41.

Here we show that Whi7 plays a new role in Start regulation independent from the control of Cln3 localization. Our results demonstrate that Whi7 is an unstable cell cycle regulated protein that acts as a genuine paralog of Whi5 repressing the Start transcriptional program.

Results
Whi7 level and phosphorylation is cell cycle regulated. Many cell cycle regulators are periodic proteins whose level fluctuates through the cell cycle. Because of that, we carried out an analysis of Whi7 protein in synchronized cultures. After release from a telophase arrest induced by a thermosensitive cdc15 mutation, progression through the cell cycle was analyzed by the presence of bud and number of nuclei (Fig. 1a) and the level of mitotic Clb2 cyclin or CKI Sic1 proteins (Fig. 1b). Clb2 decay and Sic1 accumulation reflected mitotic exit at approximately 40 min; later on, Sic1 degradation and budding marked the execution of Start at ~60 min; the appearance of Clb2 marked the G2 phase at 90 min, whereas progression through anaphase was revealed by the increase in cells with segregated nuclei at 130 min. As it is observed in Fig. 1b, Whi7 migrates in SDS-PAGE as multiple bands, which correspond to distinct phosphorylated states since lambda phosphatase treatment resulted in the migration as a single band of higher mobility (Supplementary Fig. 1). Whi7 level oscillates along the cell cycle, increasing in early G1 before Start, peaking in G2 and decaying in mitosis. Importantly, changes in Whi7 phosphorylation along the cell cycle were also observed, Whi7 becoming hyperphosphorylated as cells progress from early G1 to mitosis. In conclusion, our results revealed that Whi7 is cell cycle regulated and suggest two states along the cell cycle: one associated with hyperphosphorylation and higher protein level from early G1 to G2/M, and a second one associated with hypophosphorylation and lower protein level in M/early G1.

Whi7 is an unstable protein degraded mainly via SCF^[Grr1]. Many cell cycle regulators are unstable proteins. Therefore, we analyzed Whi7 protein stability by translational shut-off experiments. The result indicated that Whi7 is indeed an unstable protein with a half-life of approximately 20 min at 25 °C and <10 min at 37 °C (Supplementary Fig. 2).

Whi7 was stabilised in the pre1 pre2 proteasome mutant strain (Fig. 2a), indicating that degradation of Whi7 is accomplished by the ubiquitin–proteasome pathway. Two ubiquitin ligases are involved in cell cycle regulation: SCF and APC. Whi7 stability was analyzed in mutant strains in either the SCF subunit Cdc53 or the APC subunit Cdc16. As it can be observed in Fig. 2b, c, while Whi7 remains highly unstable in cdc16 mutant cells, it was highly stabilised when Cdc53 was inactivated. This indicates that the ubiquitin-ligase SCF mediates Whi7 degradation.

SCF recognizes specific cell cycle substrates mainly by means of two F-protein subunits: Cdc4 and Grr1. Whi7 still showed a high instability in the absence of Cdc4, although somewhat lower to that observed in the wild-type strain (Fig. 2d). On the contrary, Whi7 was highly stabilized in the grr1 mutant cells (Fig. 2e). This indicates that Grr1 is the major F-protein involved in Whi7 degradation. In the case of Cln3, which is also degraded by Grr1, it has been demonstrated that the insensitivity to Cdc4 is due to
Cdc4 nuclear localization instead of a genuine Cdc4 inability to recognize Cln3<sup>36</sup>. However, no changes in Whi7 stability were observed when nuclear export of Cdc4 was forced by the fusion of a nuclear export signal (Cdc4-NES), confirming a residual role for Cdc4 in Whi7 degradation (Supplementary Fig. 3). Finally, we detected a physical interaction between Whi7 and Grr1 (Fig. 2f). In conclusion, all these results revealed that Whi7 is an unstable protein, degraded mostly via the SCF<sup>Grr1</sup> ubiquitin ligase.

**Whi7 stability is cell cycle regulated by Cdc28 phosphorylation.** Stability of cell cycle regulators fluctuates along the cell cycle. To test whether Whi7 degradation could be cell cycle regulated, protein stability was studied at different cell cycle stages. When cells were blocked in metaphase after incubation with nocodazole, Whi7 showed a short half-life similar to that observed in asynchronous cultures (Fig. 3a). Whi7 was also highly unstable in cells arrested in telophase in a <i>cdc15</i> mutant strain (Fig. 3b). To test stability in G1 cells, cycloheximide was added 50 min after release from a <i>cdc15</i>-induced arrest; the absence of budding and the presence of Sic1 confirmed that cells remain in G1 along the experiment. On the contrary to that observed in G2/M and telophase, Whi7 remained stable in G1 cells. The same result was observed in G1 cells obtained by depletion of Cln cyclins (Fig. 3c).

It is noteworthy that the stable Whi7 protein appears in the western blot as the non-phosphorylated band, strongly suggesting that Whi7 stability is controlled by phosphorylation. This is consistent with the observation that Whi7 degradation depends on the SCF pathway, which requires phosphorylation of target protein

**Vector**

**pWhi7-HA**

**No tag**

**Whi5-HA**

**Input**

**Unbound**

**IP**

**Vector**

**pWhi7-HA**

**No tag**

**Whi5-HA**

**Input**

**Unbound**

**IP**

**Swi6-myc**

**mbp1swi4WtNo tag**

**Swi4-myc**

**α-myf**

**α-HA**
proteins. The CDK Cdc28 is a good candidate to mediate phosphorylation-dependent degradation of Whi7. We observed that Whi7 was stabilized in cdc28 mutant cells, accumulating in a non-phosphorylated form (Fig. 3d). Moreover, Whi7-NP (a Whi7 variant with all the Cdc28 phosphorylation consensus sites mutated) remains totally stable (Fig. 3e). Consistently, interaction with Grr1 is loss in the non-phosphorylatable Whi7 protein (Fig. 2f).

To date, Cln3 is the only cyclin known to drive Whi7 phosphorylation. The fact that Whi7 was phosphorylated and unstable in G2/M and telophase arrested cells, suggests that other cyclins are involved. In fact, no differences in Whi7 mobility pattern and stability were observed in cln3 when compared to wild-type cells, which demonstrated that other cyclins distinct from Cln3 are also responsible for Whi7 phosphorylation and degradation (Supplementary Fig. 4a). Supporting this, Whi7 protein was partially stabilized in a mutant strain in Clb1-4 cyclins (Supplementary Fig. 4b) and after inactivation of Cln1 and Cln2 in cdc4 mutant cells (Supplementary Fig. 4c).

In summary, our results indicated that Whi7 is an unstable protein whose degradation is cell cycle regulated by Cdc28-dependent phosphorylation: the protein is stable only in G1, the period of the cell cycle with no CDK activity.

**Whi7 has a Cln3-independent function in repressing Start.** We wonder whether Start regulation by Whi7 could involve other mechanisms distinct from the described Whi7 role in Cln3 cytosolic retention.

In a wild-type background, inactivation of Whi7 caused a significant decrease in the percentage of unbudded cells in asynchronous cultures: 18.9 ± 2.7 in whi7 compared to 24.3 ± 2.4 in wild type (budding index values are mean and s.d. derived from at least five independent culture henceforth). This is in agreement with the reported decrease in cell size at budding41 indicating a shortened G1 phase. However, this effect did not alter the cell size distribution in asynchronous cultures, probably due to compensation in other cell cycle stages (Supplementary Fig. 5). In the case of cln3 mutant cells, which show an increased cell size due to a defective Start activation, a reduction in the percentage of unbudded cells was also evident when Whi7 was inactivated (31.1 ± 2.4 compared to 40.5 ± 3.1). Importantly, in this case WHI7 deletion manifested a mild, but significant, reduction in cell size in asynchronous cultures (Fig. 4a). This result suggests that Whi7 mediates some Start function independently from Cln3.

To examine the influence of Whi7 on the timing of G1/S transition, G1 phase length was investigated in cln3 mutant cells. After release from a cdc15-induced telophase arrest, both WHI7 and whi7 cells exit from mitosis (marked by Sic1 accumulation) with similar kinetics. However, Start execution (marked by Sic1 disappearance and budding) was advanced ~10 min in the absence of Whi7 (Fig. 4b–d and Supplementary Fig. 6). These observations clearly demonstrate that Whi7 represses Start progression by a mechanism that is independent from Cln3 regulation.

**Whi7 associates with Start gene promoters in G1.** Whi7 is related to Whi5 at sequence level. Therefore, it is tempting to speculate the possibility that Whi7 could play a new role in cell cycle control related to transcriptional regulation. We investigated the association of Whi7 to genes of the G1/S transcriptional program by chromatin immunoprecipitation (ChIP). Cells were synchronized by telophase arrest and release, and the specific purification of DNA fragments from CLN2 and RNR1 promoters in immunoprecipitated Whi7 samples was assayed. As it is observed in Fig. 5a, a transient binding of Whi7 to both CLN2 and in a lesser extent to RNR1 promoter was detected after release, peaking at the G1 phase, as deduced by the absence of budding and the presence of Sic1. Concomitant with Start execution (budding and Sic1 degradation), Whi7 binding decays. Whi7 association to CLN2 promoter was also detected with a genomic GFP-tagged WHI7 (Supplementary Fig. 7). Association to Start genes was also observed when cells express the non-phosphorylatable Whi7-NP variant, indicating that phosphorylation by Cdc28 is not required for binding.

To better characterize Whi7 binding during G1, we used a G1-arrest induced by Cln cyclins depletion. Whi7 is not found associated to CLN2 promoter in arrested cells but, a transient binding before Start was observed after release from the arrest (Fig. 5b). In conclusion, Whi7 associates with the G1/S gene promoters in late G1 and is released at Start; this resembles the action of Whi5 and clearly pointed to a new role for Whi7 in Start regulation through the control of the Start transcriptional program.

To evaluate the relationship between Whi7 binding to promoters and Start transcriptional activation, we analyzed in parallel CLN2 gene expression. Whi7 dissociation correlated with CLN2 transcriptional activation (Fig. 5c). Moreover, deletion of WHI7 overcame, although partially, the defective SBF driven transcription of a cln3 mutant strain, and overexpression of WHI7 reduced expression of the SBF-regulated SCB:lacZ reporter (Fig. 5d). All these observations support a role of Whi7 as a transcriptional repressor of G1/S specific genes.

**Whi7 binds to the SBF transcription factor.** The Start transcriptional program is mediated by the related SBF and MBF transcriptional factors. To test whether Whi7 acts through one of them, the binding of Whi7 to CLN2 (primarily regulated by SBF) and RNR1 (primarily regulated by MBF) was investigated in

---

**Fig. 5** Analysis of Whi7 function in transcription at Start. a Cultures of cdc15 sici-myc whi7 (JCY1843) transformed with the pWHI7 or pWHI7-NP centromeric plasmid were arrested in telophase by incubation for 3 h at 37 °C (>95% of cells arrested). After the release from the arrest, Whi7 binding to CLN2 and RNR1 promoter was investigated by ChIP assays. Western blot shows Whi7, Sic1, and Cdc28 (as loading control). Cell cycle progression was monitored by the oscillations of Sic1 and bud emergence that indicated execution of Start at 60 min. b Cultures of GAL1:CLN3 cln1 cln2 WHI7-GFP (JCY208) were arrested in G1 by incubation for 3 h in YPD medium. Then, cells were transferred to YPGal medium and Whi7 binding to CLN2 promoter was investigated by ChIP assays. Western blot shows Whi7 and Cdc28. Cell cycle progression was monitored by bud emergence that indicated execution of Start at 45 min. c The level of CLN2 mRNA relative to ACT1 mRNA as a control was analyzed by quantitative RT-PCR in cells transformed with the pWHI7 plasmid. d β-galactosidase activity in extracts from wild type (W303), cln3 (MT244), and cln3 whi7 (JCY1868) strains (left) as well as from wild-type cells containing a control vector or the pGAL1::WHI7 plasmid (right), transformed with the p5CB::lacZ reporter gene. e Whi7 binding to CLN2 and RNR1 promoter was investigated by ChIP assays in asynchronous cultures of wild type (W303), swi4 (JCY167), and mbp1 (JCY624) and in α-factor arrested cultures of wild type (W303), swi4 (JCY167), and swi6 (JCY325) strains transformed with the pWHI7 plasmid or a control vector (no tag). f Cells expressing a myc-tagged Swi4 (JCY1879) or myc-tagged Swi6 (JCY6222) proteins at endogenous level were transformed with the pWHI7 plasmid or a control vector. Whi7 was immunoprecipitated from crude extracts and the presence of Whi7, Swi4-myc, and Swi6-myc in the input, unbound, and immunoprecipitated fractions was determined by western analysis. The same experiment was carried out with cells expressing a HA-tagged Whi5 and either myc-tagged Swi4 (JCY1984) or myc-tagged Swi6 (JCY1982). Values in d and e are the mean and s.d. derived from at least three experiments.
mutant strains in the Swi4 and Mbp1, specific components of SBF and MBF, respectively. The results revealed that in the absence of Swi4, Whi7 association to both CLN2 and RNR1 was severely reduced whereas in the absence of Mbp1 there was a very slight or no effect (Fig. 5e). Moreover, binding of Whi7 to CLN2 promoter was also severely affected by the absence of Swi6 (Fig. 5e). This result demonstrated that Whi7 binds Start gene promoters mostly in a SBF-dependent manner.

To further characterize the SBF-Whi7 connection, we carried out co-immunoprecipitation assays. As shown in Fig. 5f, both Swi6 and Swi4 selectively co-purified with immunoprecipitated Whi7 in a range similar to that observed with Whi5. These results provide support for a specific physical interaction of Whi7 with Swi4 and Swi6 in vivo.

**Whi7 overexpression causes a G1 arrest in cln3 mutant cells.** To further demonstrate a Whi7 repressor role independent from Cln3, we determined the effect of overexpressing WHI7 from the GAL1 promoter. In wild-type cells, there was no significant effect on cell growth but the percentage of unbudded cells in mid-log cultures raised from 32.2 ± 2.1 (vector) to 49.4 ± 2.7 (GAL1:WHI7)
WHI7 plasmid), which is in agreement with the reported increase in cell size in budding cells indicative of an expanded G1 phase. Nevertheless, high levels of Whi7 were lethal in the absence of Cln3 (Fig. 6a). This is not due to differences in Whi7 expression between wild-type and cln3 cells (Fig. 6b). Analysis of cells after WHI7 induction indicated a first cycle arrest at Start with the accumulation of more than 97% of single-nucleated large unbudded cells (Fig. 6c, d).

Next, ChIP assays demonstrated an increased Whi7 association with CLN2 and RNR1 promoters in Start blocked cln3 cells (Fig. 6e). This strongly suggests that Whi7 must cause G1 arrest by repressing the Start transcriptional program. In fact, analysis of CLN2 mRNA in cells overexpressing Whi7 confirmed that gene expression was repressed (Fig. 6f). Moreover, ectopic expression of CLN2 suppressed the lethality of WHI7 overexpression in cln3 cells, a typical property of mutants in the Start transcriptional program (Fig. 6g).

In conclusion, high levels of Whi7 caused repression of the Start transcriptional program leading to a G1 arrest in cln3 mutant cells. This confirms that first, Whi7 plays a role in Start regulation mediating Start transcriptional program repression, and second, that this is a new role independent from its known function in Cln3 regulation.

Whi7 function depends on the presence of SBF. As described above, WHI7 deletion causes a reduction in cell size in a strain genetically compromised for Start due to a cln3 mutation.
Interestingly, WHI7 deletion had no effect on cell size in the case of swi4 or swi6 mutation (Fig. 4a). This indicates that Whi7 effect on cell size depends on the presence of SBF but does not require Cln3.

The effect of WHI7 overexpression in either swi4 or swi6 mutant cells was also investigated. It caused a reduction in cell growth rate and a small increase in the percentage of unbudded cells, in particular in the case of swi4 cells, which is consistent with the known Whi7 regulation of Cln3 (Supplementary Fig. 8). Importantly, and contrary to what was observed in the case of cln3 cells, high levels of Whi7 were not lethal in swi4 and swi6 mutant cells. This strongly suggests that Whi7 induced G1 arrest is mediated by SBF function.

**Whi7 is functionally redundant with the Start repressor Whi5.**

Given the similarities between Whi7 functions described above with the role of the Start transcriptional repressor Whi5, we decided to compare both proteins. As described here, Whi7 is an unstable protein degraded by SCF^Grr1_. Nevertheless, Whi5 is a pretty stable protein when compared to Whi7 (Fig. 7a).

We also investigated CLN2 promoter association of Whi7 and Whi5 simultaneously in the same synchronized cells. Both proteins showed the same binding kinetics (Fig. 7b). This result also indicates that both factors are simultaneously occupying the CLN2 promoter.

Using the same tagging cassette, we observed approximately a 50% reduced protein level of Whi7 compared to Whi5 (Fig. 7c). In parallel ChIP assays, binding of both proteins to different genes including CLN2, RNR1 and SBF-regulated cell-wall genes FKS1 and MNN1 was detected in all cases, but differences in their specificity were consistently observed, Whi5 showing a preferred binding compared to Whi7 in the case of CLN2 (Fig. 7d).

Next, we investigated whether inactivation of WHI7 and WHI5 have additive effect in cell size. Loss of WHI7 does not affect the reduced cell size characteristic of a whi5 mutant strain (Supplementary Fig. 5b). However, WHI7 inactivation further reduces the cell size of a whi5 mutant in a cln3 background (Fig. 7e). This indicates that both proteins contribute to the control of cell size. It is noteworthy that cln3 whi5 whi7 cells are bigger than whi5 whi7 cells, which point to an additional function for Cln3 different from inactivating Whi5 and Whi7 in the control of Start. We also observed additive effect of Whi5 and Whi7 overexpression in the control of cell size, reinforcing the idea that both proteins act in parallel (Fig. 7f). Finally, we demonstrated that WHI7 overexpression in whi5 cells restores a normal cell size (Fig. 7g). This is an important observation that indicates that Whi7 protein is able to substitute Whi5 in Start regulation.

**Discussion**

Whi7 is related at sequence level to Whi5 transcriptional repressor, the yeast functional paralog of Rb protein in mammalian cells. This indicates a common evolutionary origin and suggests that both proteins could develop similar functions. In this work we provide new clues about Whi7 function in cell cycle regulation, characterizing Whi7 as an unstable cell-cycle regulated protein and bringing to light a novel function as a transcriptional repressor in Start.

The analysis of Whi7 protein along the cell cycle indicates that Whi7 is present in multiple phosphorylation states. Electrophoretic migration of Whi7 in a cdc28 mutant and a Whi7 mutated in all the putative CDK phosphorylation sites was similar to that observed in lambda phosphatase assays, suggesting that CDK is the only kinase involved in Whi7 phosphorylation. However, it cannot completely be excluded that other kinases may phosphorylate Whi7, as occurs for Whi5. It was known that Whi7 is phosphorylated by Cln3-Cdc28 and consistently its phosphorylation pattern changed in G1/S. Here, we found Whi7 in a phosphorylated state along basically the whole-cell cycle. Importantly, the degree of phosphorylation changes drastically. It begins to rise from mid-G1 prior to Start until mitosis, to decrease in mitotic exit. This temporal window matches the cell cycle period with CDK activity. Moreover, it strongly suggests that phosphatase Cdc14 may be responsible for Whi7 dephosphorylation, similarly to that reported for Whi5.

Cell cycle regulators are often unstable proteins whose degradation is regulated throughout the cycle. We have identified that Whi7 is degraded mainly via the ubiquitin-ligase SCF^Grr1_. However, the fact that Whi7 is not completely stable in a grl1 deletion mutant suggests that other pathways could contribute to its degradation or that Whi7 might have a high intrinsic instability. We also show that Whi7 degradation, as usually occurs in SBF targets, is dependent on CDK phosphorylation. This is consistent with the fact that Whi7 is stable only in G1, the period of low CDK activity. Cln3-Cdc28 is the first CDK activity appearing in the cycle, so it is reasonable to think that it initiates Whi7 degradation, but Whi7 is also unstable in G2/M or telophase and in cln3 mutant cells and it is stabilized by the inactivation of clb1-4 or cln1-2. Therefore, we propose that any CDK can phosphorylate Whi7 targeting it for degradation via SCF^Grr1_, as occurs with other key cell cycle regulators such as the CKI Sic1 or the APC ubiquitin-ligase co-activator Cdh1.

Recently, Whi7 had been connected to cell cycle regulation based on the control of Cln3 cytosolic retention. Here we describe that Whi7 inactivation produces a significant reduction in cell size and an advance in Start in cln3 mutant cells. This is an important point because first, it indicates that Whi7 plays a key role as a negative Start regulator, and second, it highlights a new function distinct from its known role as regulator of Cln3. Whi7 showed sequence similarities with the Start regulator Whi5 but to date, no transcriptional function had been described for Whi7. Our results provide at last the demonstration that Whi7 is able to develop the same function as Whi5, binding and repressing the promoters of G1/S regulated genes. Several results support this idea: Whi7 associates with CLN2 and RNR1 promoters in G1 and its dissociation coincides with expression of G1/S genes, as Whi5 does; Whi7 inactivation overpass a defect in the expression of the SCBlacZ reporter in cln3 mutant cells and its overexpression is able to partially repress SCB-lacZ expression in wild-type cells; WHI7 overexpression is lethal in a cln3 mutant causing an arrest at Start because it remains attached to the promoters and maintains transcription locked; finally, Whi7 overexpression recovers normal cell size in whi5 mutant cells clearly demonstrating that Whi7 is capable of performing the same function as Whi5.

Periodic expression in G1/S is mediated by SBF and MFB. Our results indicate that Whi7 binds to SBF regulated (CLN2) as well as to MFB regulated (RNR1) genes. However, Whi7 binding is not affected by Mbp1 mutation but is impaired by Swi4 or Swi6 mutation, confirming that binding to both CLN2 as RNR1 promoters is mediated by SBF. This is consistent with the detection of a lower Whi7 binding in RNR1 than in CLN2. In addition, it has to be considered that SBF is indeed able to bind to RNR1 promoter.

Overall, our results provide new insights in the characterization of Start control by demonstrating that Whi7 is, as Whi5, a repressor of the Start transcriptional program. Therefore, we propose Whi7 to be a functional paralog of Whi5. This deepens our knowledge of how Whi7 controls cell cycle. Thus, Whi7 plays a double repressive role in the execution of Start mediating: (1) the retention of Cln3 in the ER as previously described, and (2)
the repression at target promoters of Cln3 initial trigger and Cln1,2 feedback activation of SBF-dependent transcription (Fig. 8). This two-way lock mechanism highlights the necessity for robust controls in cell cycle regulation.

An open question is the role of Whi7 phosphorylation in this new function in transcription. A non-phosphorylatable version of Whi7 associates and dissociates from promoters normally. In the case of Whi5, mutations of all phosphorylation sites have no overt effect on Start and only when combined with non-phosphorylatable Swi6 are deleterious. Disengagement of Whi7 from SBF could also proceed via multiple redundant phosphorylation events in Whi7, Swi6, and Swi4. Supporting that Whi7 phosphorylation could help to release Whi7 from promoters, we observe largest promoter association with Whi7-NP compared to wild-type protein.

The fact that Whi7 overexpression restores normal cell size in a whi5 mutant clearly reflects that Whi7 is able to perform the same function as Whi5. But what is the relevance of Whi7 in Start compared to Whi5? While Whi5 inactivation causes a dramatic reduction in cell size, Whi7 inactivation does not alter size distribution of wild-type or whi5 cells. Only in a cln3 mutant background we detect a cell size decrease when Whi7 is inactivated, and this effect is smaller than that observed by inactivating Whi5. Also, overexpression of Whi5 but not Whi7 caused a severe increase in cell size. Thus, the effect on cell size indicates that Whi5 is more critical than Whi7 for the correct timing of Start. In fact, ChIP assays revealed a 3–4 times more enrichment of CLN2 promoter fragment with Whi5 than Whi7, which could suggest a greater presence of Whi5 than Whi7 in the CLN2 promoter. However, it is important to note that we have detected simultaneous binding of Whi5 and Whi75 to CLN2 promoter in the same cells, indicating that Whi7 is indeed involved in the regulation of Start transcription. Furthermore, Whi7 and Whi5 have additive effects on cell size control. Therefore, we propose a model in which the SCB sites of target promoters are occupied by SBF repressed largely by Whi5 but also by Whi7.

The presence of two repressor proteins should represent an evolutionary advantage to the cell. Functional redundancy between proteins is a hallmark in cell cycle regulation. Moreover, there could be a functional specialization of Whi7 and Whi5. Whi7 might be participating in a subset of genes and/or conditions. Whi7, but not Whi5, protein levels are specifically increased in mother cells after twelve generation, which could point to a specific role for Whi7 in restraining cell cycle entry during replicative aging. Whi7 binds to CLN2 promoter in the presence of hydroxyurea and it was isolated as a suppressor of DNA-damage checkpoint rad53 mutant, suggesting a function in the response to genotoxic stress. Furthermore, WHI7 gene expression is regulated by the cell-wall integrity (CWI) pathway and it is known that SBF participates in gene expression of cell-wall genes and the CWI pathway regulates Swi4 and Swi6. Thus, cells might use Whi7 for transient responses under certain stress conditions.

The similarity in the regulatory control system of G1/S transition between yeast and mammalian are staggering. In mammalian cells, passage through the restriction point involves the turn-on of a wave of gene expression controlled by the E2F-DP family of transcription factors. Until late G1, transcription is repressed by the association of Retinoblastoma family proteins (Rb, p107, p130) to E2Fs. Initial activation is triggered by cyclin D-CDK4,6 phosphorylation of Rb, which causes its dissociation from E2Fs. As a consequence, cyclin E gene is expressed, providing a positive feedback in which cyclin E-CDK2 phosphorylate Rb in order to maintain transcriptional activation. It is easy to recognize the same regulatory strategy in Start control in yeast, where the roles of cyclin D, E2F-DBPs, Rb, and cyclin E are played by Cln3, SBF/MBF, Whi5, and Cln1,2 respectively. To date however, Whi5 was the only factor in yeast involved in maintaining the Start transcriptional program repressed before Start. Here, we have demonstrated that, as occurs in mammalian cells, yeast also uses multiple transcriptional repressors before Start, further extending the parallelism between yeast and mammalian cells. Due to the conserved regulatory pathways, understanding the interplay between Whi5 and Whi7 repressors in yeast could provide insight into how distinct Rb family proteins interweave in mammalian cell cycle control. The fact that an Rb family member is mutated in nearly all tumors underlines the importance of studying the role of these G1 repressors, and given the power of yeast as a model system, further investigation in Whi7 and Whi5 is warranted.

Methods

Strains and plasmids. Yeast strains used in this work are shown in Supplementary Table 1. Centromeric plasmids pWHI7, pWHI7-NP, and pGAL1:WHI7 expressing HA-tagged wild-type Whi7, Whi7 protein mutated in all canonical CDK phosphorylation sites and wild-type Whi7 under the control of the GAL1 promoter respectively, are a gift from Dr. M. Aldea. Centromeric plasmid pGAL1:WHI5 expressing myc-tagged Whi5 under the control of the GAL1 promoter is a gift from

Fig. 8 Model of Whi7 function in the control of Start. Whi7 plays a double repressive role in the execution of Start: it mediates the retention of Cln3 in the endoplasmic reticulum and it collaborates with Whi5 in the repression of SBF-dependent transcription.

Methods

Strains and plasmids. Yeast strains used in this work are shown in Supplementary Table 1. Centromeric plasmids pWHI7, pWHI7-NP, and pGAL1:WHI7 expressing HA-tagged wild-type Whi7, Whi7 protein mutated in all canonical CDK phosphorylation sites and wild-type Whi7 under the control of the GAL1 promoter respectively, are a gift from Dr. M. Aldea. Centromeric plasmid pGAL1:WHI5 expressing myc-tagged Whi5 under the control of the GAL1 promoter is a gift from...
Gene expression analysis. Approximately 2 × 10^8 cells were broken in a FastPrep under the control of the mild. Approximately 5 × 10^8 cells were calculated with the investigated promoter fragments in the immunoprecipitated sample by quantitative PCR in a DNA Engine Peltier Termal Cycler (Bio Rad) using the proteinase K and DNA was purified with the High Pure PCR product purification kit (Roche Diagnostics). Co-immunoprecipitated DNA was analyzed in triplicate by quantitative PCR in a DNA Engine Peltier Termal Cycler (Bio Rad) using the SYBR Premix Ex Taq Th RNase H Plus Green with ROX (Takara). DNA analysis were fragments from CLN2, NDR1, FKSI, and MNN1 promoters and an interrogative region as a control. Whi7 or Whi5 binding values indicates the specific enrichment of the immunoprecipitated promoter fragments in the immunoprecipitated sample compared to the whole-cell extract (input) using the interrogative region as a control, calculated with the ΔΔCT method. Values are relative to the no tag control strain (value of 1 equivalent to no specific enrichment).

Protein stability assays. To evaluate Whi7 and Whi5 stability, 100 μg mL^−1 cycloheximide was added to exponentially growing cells or cells incubated during 3 h at 37 °C when termosensitive mutants were used. Samples were harvested at the indicated times and protein decay was analyzed by western blot analysis. Bands were quantified with ImageQuant LAS 4000mini biomolecular imager (GE Healthcare). Two-three experiments with independent transformants were carried out for each strain. A representative experiment is shown.

Chromatin immunoprecipitation analysis. Approximately 5 × 10^8 cells were cross-linked by a 15 min incubation after the addition of formaldehyde to 1% (v/v) to the growth medium, followed by a 5 min incubation after the addition of glycine to 125 mM. Cells were washed and resuspended in 300 μL of lysis buffer (50 mM HEPES-KOH pH 7.9, 40 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (v/v) sodium deoxicholate, 1 mM PMSE, 1 mM benzamidine and Complete Mini protease inhibitor (Roche Diagnostics), and lysed by vortexing with glass beads for 30 min at 4 °C. Lysis buffer was supplemented to a final volume of 600 μL, chromatin was then fragmented by sonication and the sample was centrifuged at 13,400 × g for 15 min. 20 μL from the supernatant was collected as a control of whole-cell extract (input) and the remaining was incubated with orbital rotation for 2 h at 4 °C with Dynabeads Protein G (Invitrogen) previously bound to an HA-probe (F-7) antibody (Santa Cruz Biotechnology Inc. Cat. No: SC-7392) or monoclonal GFP antibody (Roche Diagnostics, Cat. No: 11814460001). Beads were then washed 4 times in PBS (150 mM NaCl, 40 mM Na₂HPO₄, 10 mM NaH₂PO₄) containing 0.5% (v/v) SDS. Elution of bound protein was carried out twice with 40 μL of 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% (v/v) SDS, by heating at 65 °C for 8 min. Cross-linking was reversed by overnight incubation at 65 °C with shaking. The eluted sample was digested for 90 min at 37 °C with 0.33 μg mL^−1 proteinase K and DNA was purified with the High Pure PCR product purification kit (Roche Diagnostics). 2. Johnson, A. & Skotheim, J. M. Start and the restriction point. Curr. Opin. Cell Biol. 25, 717–723 (2013).

Bertioli, C., Skotheim, J. M. & de Bruin, R. A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518–528 (2013). 3. Massague, J. G1 cell-cycle control and cancer. Nature 432, 298–306 (2004). 4. Breeden, L. Periodic transcription: a cycle within a cycle. Curr. Biol. 13, R31–R38 (2003). 5. Wittenberg, C. & Reed, S. I. Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptiones. Oncogene 24, 2764–2775 (2005).

Cell size analysis. Cell size was analyzed in exponentially growing cells after brief sonication in a particle count and size Analyzer Z2 (Beckman Coulter). Graphs are the mobile average of histograms from values from at least six independent cultures.

Data availability. The data that support the findings of this study are available within the article and its Supplementary Information, and from the corresponding author on reasonable request.

Received: 28 November 2016 Accepted: 24 June 2017 Published online: 24 August 2017

References

1. Morgan, D. O. in The Cell Cycle: principles of control 28–54 (New Science Press, 2010). 2. Johnson, A. & Skotheim, J. M. Start and the restriction point. Curr. Opin. Cell Biol. 25, 717–723 (2013).

Bertioli, C., Skotheim, J. M. & de Bruin, R. A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518–528 (2013). 3. Massague, J. G1 cell-cycle control and cancer. Nature 432, 298–306 (2004). 4. Breeden, L. Periodic transcription: a cycle within a cycle. Curr. Biol. 13, R31–R38 (2003). 5. Wittenberg, C. & Reed, S. I. Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptiones. Oncogene 24, 2764–2775 (2005).

Bean, J. M., Sigga, E. D. & Cross, F. R. High functional overlap between Mll1 cell-cycle box binding factor and Swi6/6 cell-cycle box binding factor in the G1/S transcriptional program in Saccharomyces cerevisiae. Genetics 171, 49–61 (2005).

de Bruin, R. A. et al. Constraining G1-specific transcription to late G1 phase: the MBF-associated coressor Nrm1 acts via negative feedback. Mol. Cell 23, 483–496 (2006).

Koch, C., Moll, T., Neuberg, M., Ahorn, H. & Nasmyth, K. A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase. Science 261, 1551–1557 (1993).

Costanzo, M. et al. CDK activity antagonizes Whi5, an inhibitor of G1/S transcription in yeast. Cell 117, 899–913 (2004).

de Bruin, R. A., McDonald, W. H., Kalashnikova, T. I., Yates, J. 3rd & Wittenberg, C. Cln3 activates G1-specific transcription via phosphorylation of the SBF bound repressor Whi5. Cell 117, 887–898 (2004).
12. Drick, L., Bohm, T. & Nasmyth, K. Roles and regulation of Cln-Cdc28 kinases at the start of the cell cycle of Saccharomyces cerevisiae. EMBO J. 14, 4803–4813 (1995).

13. Stuart, D. & Wittenberg, C. CLN3, not positive feedback, determines the timing of CLN2 transcription in cycling cells. Genes Dev. 9, 2780–2794 (1995).

14. Wang, H., Gari, E., Verges, E., Gallego, C. & Aldea, M. Recruitment of Cdc28 by Whi3 restricts nuclear accumulation of the G1 cyclin-Cdk complex to late G1. EMBO J. 23, 180–190 (2004).

15. Willems, A. R., Schwab, M. & Tyers, M. A hitchhiker of CLN2 transcription in cycling cells. PLoS ONE 4, e3400 (2009).

16. Charvin, G., Oikonomou, C., Sigia, E. D. & Cross, F. R. Origin of irreversibility of cell cycle start in budding yeast. PLoS Biol. 8, e1000284 (2010).

17. Eser, U., Falleur-Fettig, M., Johnson, A. & Skotheim, J. M. Commitment to a cell cycle transition precedes genome-wide transcriptional change. Mol. Cell 43, 515–527 (2011).

18. Skotheim, J. M., Di Talia, S., Sigia, E. D. & Cross, F. R. Positive feedback of G1 cyclins ensures coherent cell cycle entry. Nature 454, 291–296 (2008).

19. Schmoller, K. M., Turner, J. J., Koivomagi, M. & Skotheim, J. M. The dilution of the cell cycle inhibitor Whi3 controls budding yeast cell size. Nature 526, 268–272 (2015).

20. Ferrezuelo, F. et al. The critical size is set at a single-cell level by growth rate to attain homeostasis and adaptation. Nat. Commun. 3, 1012 (2012).

21. Wang, H., Carey, L. B., Cai, Y., Wijnen, H. & Futcher, B. Recruitment of Cln3 to promoters controls cell cycle entry via histone deacetylase and other Cdk-dependent mechanisms. Mol. Cell 35, 381 (2009).

22. Koch, C., Schleiffer, A., Ammerer, G. & Nasmyth, K. Switching transcription on and off during the yeast cell cycle: Cln/Cdc28 kinases activate bound transcription factor binding site motif in cycling yeast. Mol. Cell Biol. 25, 6049 (2005).

23. Miles, S., Croxford, M. W., Abeyesinghe, A. P. & Breeden, L. L. Msa1 and Msa2 modulate G1-specific transcription to promote G1 arrest and the transition to quiescence in budding yeast. PLoS Genet. 12, e1006886 (2016).

24. Takahata, S., Yu, Y. & Stillman, D. J. The EZF functional analogue SBF recruits the Rpd3(L) HDAC, via Whi5 and Sib1, and the FACT chromatin reorganizer, to yeast G1 cyclin promoters. EMBO J. 28, 3378–3389 (2009).

25. Gustafsson, M. K., Schwab, M. & Andrews, O. G1 transcription factors are differentially regulated in Saccharomyces cerevisiae by the Swi6-binding protein Sib1. Mol. Cell Biol. 23, 5064–5077 (2003).

26. de Bruijn, R. A., Kalashnikova, T. I. & Wittenberg, C. Sib1 collaborates with other regulators to modulate the G1-specific transcriptional circuit. Mol. Cell Biol. 28, 6195–6198 (2008).

27. Huang, D. et al. Dual regulation by pairs of cyclin-dependent protein kinases and histone deacetylases controls G1 transcription in budding yeast. PLoS Biol. 7, e1000188 (2009).

28. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6, 369–381 (2006).

29. Peters, J. M. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat. Rev. Mol. Cell Biol. 7, 644–656 (2006).

30. Skaa, J. R. & Pagano, M. Control of cell growth by the SCP and APCC ubiquitin ligases. Curr. Opin. Cell Biol. 21, 816–824 (2009).

31. Willems, A. R., Schwab, M. & Tyers, M. A hitchhiker’s guide to the cullin ubiquitin ligases: SCF and its kin. Biochem. Biophys. Acta 1695, 133–170 (2004).

32. Lander, S. J., Doyle, J. P., Toczycki, D. P. & Benanti, J. A. F-box protein specificity for G1 cyclins is dictated by subcellular localization. PLoS Genet. 8, e1002851 (2012).

33. Koivomagi, M. et al. Cascades of multisite phosphorylation control Sic1 destruction at the onset of S phase. Nature 480, 128–131 (2011).

34. Desany, B. A., Alcasabas, A. A., Bachant, J. B. & Elledge, S. J. Recovery from DNA replication stress is the essential function of the S-phase checkpoint pathway. Genes Dev. 12, 2956–2970 (1998).

35. Traversa, A. et al. Repression of G1/S transcription is mediated via interaction of the G1B motifs of Nrm1 and Whi5 with Swi6. Mol. Cell Biol. 33, 1476–1486 (2013).

36. Jorgensen, P., Nishikawa, J. L., Breitkreutz, B. J. & Tyers, M. Systematic identification of pathways that couple cell growth and division in yeast. Science 297, 395–400 (2002).

37. Yabu, K., Parisi, E., Flores, A., Gallego, C. & Aldea, M. A Whi7-associated loop controls the G1 Cdk-cyclin complex at start. Mol. Cell 53, 115–126 (2014).

38. Taberner, F. J., Quilis, I. & Igual, J. C. Spatial regulation of the start repressor Whi5. Cell Cycle 8, 3010–3018 (2009).

39. Jyer, V. et al. Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. Nature 409, 533–538 (2001).

40. Simon, I. et al. Serial regulation of transcriptional regulators in the yeast cell cycle. Cell 106, 697–708 (2001).

41. Yiu, G. et al. Pathways change in expression during replicative aging in Saccharomyces cerevisiae. J. Gerontol. A Biol. Sci. Med. Sci. 63, 21–34 (2008).

42. Boonsma, A. et al. Characterization of the transcriptional response to cell stress in Saccharomyces cerevisiae. Yeast 21, 413–427 (2004).

43. Lagorce, A. et al. Genome-wide analysis of the response to cell wall mutations in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 278, 20345–20357 (2003).

44. Baetz, K., Moffat, J., Haynes, J., Chang, M. & Andrews, R. Transcriptional coregulation by the cell integrity mitogen-activated protein kinase Sh2 and the cell cycle regulator Swi4. Mol. Cell Biol. 21, 6515–6528 (2001).

45. Igual, J., Johnson, A. & Johnston, L. Coordinated regulation of gene expression by the cell cycle transcription factor Swi4 and the protein kinase C MAP kinase pathway for yeast cell integrity. EMBO J. 15, 5001–5013 (1996).

46. Kim, K. Y., Truman, A. W., Caesar, S., Schlenstedt, G. & Levin, D. E. Yeast Mpk1 cell wall integrity mitogen-activated protein kinase regulates nucleocytoplasmic shuttling of the Swi6 transcriptional regulator. Mol. Biol. Cell 21, 1609–1610 (2010).

47. Kim, K. Y., Truman, A. W. & Levin, D. E. Yeast Mpk1 mitogen-activated protein kinase activates transcription through Swi6/Swib6 by a noncatalytic mechanism that requires upstream signal. Mol. Cell Biol. 28, 2579–2589 (2008).

48. Cooper, K. Rb, whi3 it’s not just for metazoans anymore. Oncogene 25, 5228–5232 (2006).